Lin Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lin Wu has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Bingxun Li
The First College of Clinical Medical Science, China Three Gorges University, Yichang, China
9 shared publicationsHongxuan Xu
Department of Cardiology, Peking University First Hospital, Beijing, China
7 shared publicationsGang Li
Department of Cardiology, Peking University First Hospital, 8, Xishiku Street, West District, Beijing 100034, People's Republic of China
5 shared publicationsLu Ren
Department of Cardiology, Peking University First Hospital, 8, Xishiku Street, West District, Beijing 100034, People's Republic of China
5 shared publicationsShandong Yu
Department of Cardiology, Peking University First Hospital, 8, Xishiku Street, West District, Beijing 100034, People's Republic of China
5 shared publicationsYing Chen
Department of Cardiology, Peking University First Hospital, Beijing, China
5 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by Wolters Kluwer Health in Cardiac Research
- Vol. 2 (1) , 40-50
Histidine and the risk of incident atrial fibrillation and postablation recurrence: Evidence from 2 prospective cohorts
Background: To investigate the association between circulating histidine levels and the risk of atrial fibrillation (AF) onset and recurrence, and to explore potential underlying mechanisms. Methods: We analyzed data from 221,277 AF-free participants in the UK Biobank and from 44 patients with paroxysmal or persistent AF undergoing catheter ablation, in whom histidine was measured in both peripheral and intracardiac blood. Associations with incident and recurrent AF were evaluated using Cox proportional hazards models, subgroup analyses, and sensitivity analyses. Receiver operating characteristic analysis assessed the predictive value of histidine for AF recurrence. Mechanistic studies included a sheep AF model to examine the impact of electrical remodeling on atrial histidine metabolism, and neonatal rat cardiomyocyte experiments to assess histidine’s effects on cell viability and gene expression. Results: Over a median follow-up of 13.6 years, 14,427 participants developed new-onset AF. Higher histidine levels were associated with a lower risk of AF (hazard ratio per standard deviation: 0.95; 95% confidence interval: 0.94–0.97), with consistent findings across sensitivity analyses. In the ablation cohort, histidine predicted AF recurrence with 76% sensitivity and 77% specificity (area under the receiver operating characteristic curve = 0.75; 95% confidence interval: 0.59–0.90). In the sheep AF model, histidine levels remained stable despite increased 3-methylhistidine, indicating no effect of electrical remodeling on histidine metabolism. Histidine demonstrated a dose-dependent effect on cardiomyocyte viability, enhancing activity at nanomolar concentrations while reducing it at micromolar levels. The downregulation of oxidative phosphorylation (OXPHOS) genes at higher histidine doses, together with the reduction in relative MitoSOX intensity, suggests a dose-dependent modulation of mitochondrial function, potentially balancing energy production and oxidative stress. Conclusion: Histidine is inversely associated with AF risk and may serve as a predictive biomarker for AF recurrence. Experimental findings suggest that changes in histidine may precede AF development, supporting its potential as a modifiable metabolic target.
- 6 March 2026
- Published by Wolters Kluwer Health in Cardiac Research
- Vol. 2 (1) , 40-50
Open AccessHistidine and the risk of incident atrial fibrillation and postablation recurrence: Evidence from 2 prospective cohorts
Background: To investigate the association between circulating histidine levels and the risk of atrial fibrillation (AF) onset and recurrence, and to explore potential underlying mechanisms. Methods: We analyzed data from 221,277 AF-free participants in the UK Biobank and from 44 patients with paroxysmal or persistent AF undergoing catheter ablation, in whom histidine was measured in both peripheral and intracardiac blood. Associations with incident and recurrent AF were evaluated using Cox proportional hazards models, subgroup analyses, and sensitivity analyses. Receiver operating characteristic analysis assessed the predictive value of histidine for AF recurrence. Mechanistic studies included a sheep AF model to examine the impact of electrical remodeling on atrial histidine metabolism, and neonatal rat cardiomyocyte experiments to assess histidine’s effects on cell viability and gene expression. Results: Over a median follow-up of 13.6 years, 14,427 participants developed new-onset AF. Higher histidine levels were associated with a lower risk of AF (hazard ratio per standard deviation: 0.95; 95% confidence interval: 0.94–0.97), with consistent findings across sensitivity analyses. In the ablation cohort, histidine predicted AF recurrence with 76% sensitivity and 77% specificity (area under the receiver operating characteristic curve = 0.75; 95% confidence interval: 0.59–0.90). In the sheep AF model, histidine levels remained stable despite increased 3-methylhistidine, indicating no effect of electrical remodeling on histidine metabolism. Histidine demonstrated a dose-dependent effect on cardiomyocyte viability, enhancing activity at nanomolar concentrations while reducing it at micromolar levels. The downregulation of oxidative phosphorylation (OXPHOS) genes at higher histidine doses, together with the reduction in relative MitoSOX intensity, suggests a dose-dependent modulation of mitochondrial function, potentially balancing energy production and oxidative stress. Conclusion: Histidine is inversely associated with AF risk and may serve as a predictive biomarker for AF recurrence. Experimental findings suggest that changes in histidine may precede AF development, supporting its potential as a modifiable metabolic target.
- Open Access
- 20 January 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25 (1)
Rethinking the lipid paradox: the role of baseline characteristics in LDL-C and long-term mortality after acute myocardial infarction
Previous observations have reported inconsistent results on the association between low-density lipoprotein cholesterol (LDL-C) at presentation and long-te
- 20 January 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25 (1)
Open AccessRethinking the lipid paradox: the role of baseline characteristics in LDL-C and long-term mortality after acute myocardial infarction
Previous observations have reported inconsistent results on the association between low-density lipoprotein cholesterol (LDL-C) at presentation and long-te
- Open Access
- 28 November 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1)
N-palmitoyl glycine differentially modulates TRPM4 and TRPC5 and is causally linked to Brugada syndrome
Brugada syndrome (BrS) is an inherited cardiac arrhythmic disorder associated with an increased risk of malignant ventricular arrhythmia and sudden death. Mendelian randomisation implicated N-palmitoyl glycine (PalGly) in BrS risk and identified BrS-associated proteins (DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA), for which molecular docking further predicted moderate binding affinities with PalGly. PalGly enhanced calcium sparks in ventricular cardiomyocytes without affecting Nav1.5 or Kv4.3/KChiP2 but activated TRPC5 (EC₅₀ 104 nM), as confirmed by patch-clamp. TRPM4, a channel mediating sodium influx at negative potentials and reported to link to BrS when mutated, was directly inhibited by PalGly (IC₅₀ = 7 nM). Functionally, PalGly shortened APD in cardiomyocytes and QT in male rabbit hearts, whereas ML204 (TRPC5 inhibitor) further shortened APD in isolated cardiomyocytes. Transcriptomic and lipidomic analyses further indicated immune pathway suppression. Our study underscores the involvement of PalGly, TRPC5, and inflammation-related proteins in the pathophysiology of BrS.
- 28 November 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1)
Open AccessN-palmitoyl glycine differentially modulates TRPM4 and TRPC5 and is causally linked to Brugada syndrome
Brugada syndrome (BrS) is an inherited cardiac arrhythmic disorder associated with an increased risk of malignant ventricular arrhythmia and sudden death. Mendelian randomisation implicated N-palmitoyl glycine (PalGly) in BrS risk and identified BrS-associated proteins (DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA), for which molecular docking further predicted moderate binding affinities with PalGly. PalGly enhanced calcium sparks in ventricular cardiomyocytes without affecting Nav1.5 or Kv4.3/KChiP2 but activated TRPC5 (EC₅₀ 104 nM), as confirmed by patch-clamp. TRPM4, a channel mediating sodium influx at negative potentials and reported to link to BrS when mutated, was directly inhibited by PalGly (IC₅₀ = 7 nM). Functionally, PalGly shortened APD in cardiomyocytes and QT in male rabbit hearts, whereas ML204 (TRPC5 inhibitor) further shortened APD in isolated cardiomyocytes. Transcriptomic and lipidomic analyses further indicated immune pathway suppression. Our study underscores the involvement of PalGly, TRPC5, and inflammation-related proteins in the pathophysiology of BrS.
- Open Access
- 13 March 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2478474
Heart rate variability in patients with atrial fibrillation of sinus rhythm or atrial fibrillation: chaos or merit?
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia characterized by consistently irregular atrial and ventricular contractions. Heart rate variability (HRV) refers to the changes in the intervals between consecutive ventricular heartbeats. In sinus rhythm, HRV may be subtle and is quantitatively reflecting the dynamic interplay of the cardiac autonomic nervous system, which plays a crucial role in the onset, development, and maintenance of AF. HRV metrics, consisting of time-domain, frequency-domain, and nonlinear parameters, have been verified to vary significantly before and after AF episodes, and AF treatment-related procedures such as electrical cardioversion, ablation, and surgery of AF. Therefore, HRV may serve as a digital biomarker in predicting AF risk in long-term and acute risk period, identification of patients with AF risk in sinus rhythm and recurrence risk stratification after procedures. HRV in AF rhythm, predominantly influenced by dynamic atrioventricular node conduction under the onslaught of irregular atrial impulses, shows a huge disparity compared to that in sinus rhythm. Despite this, HRV in AF rhythm still provides valuable prognostic information, as reduced HRV may indicate a poor heart function and outcomes in patients with AF. Despite being influenced by lots of variables, HRV can still serve as an independent digital biomarker in the clinical management of AF throughout its entire lifecycle.
- 13 March 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2478474
Open AccessHeart rate variability in patients with atrial fibrillation of sinus rhythm or atrial fibrillation: chaos or merit?
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia characterized by consistently irregular atrial and ventricular contractions. Heart rate variability (HRV) refers to the changes in the intervals between consecutive ventricular heartbeats. In sinus rhythm, HRV may be subtle and is quantitatively reflecting the dynamic interplay of the cardiac autonomic nervous system, which plays a crucial role in the onset, development, and maintenance of AF. HRV metrics, consisting of time-domain, frequency-domain, and nonlinear parameters, have been verified to vary significantly before and after AF episodes, and AF treatment-related procedures such as electrical cardioversion, ablation, and surgery of AF. Therefore, HRV may serve as a digital biomarker in predicting AF risk in long-term and acute risk period, identification of patients with AF risk in sinus rhythm and recurrence risk stratification after procedures. HRV in AF rhythm, predominantly influenced by dynamic atrioventricular node conduction under the onslaught of irregular atrial impulses, shows a huge disparity compared to that in sinus rhythm. Despite this, HRV in AF rhythm still provides valuable prognostic information, as reduced HRV may indicate a poor heart function and outcomes in patients with AF. Despite being influenced by lots of variables, HRV can still serve as an independent digital biomarker in the clinical management of AF throughout its entire lifecycle.
- Open Access
- 12 March 2025
- Published by Wiley in Cancer Innovation
- Vol. 4 (2) , e70004
Inhibition of Putative Ibrutinib Targets Promotes Atrial Fibrillation, Conduction Blocks, and Proarrhythmic Electrocardiogram Indices: A Mendelian Randomization Analysis
Background: The mechanism by which ibrutinib, a Bruton's tyrosine kinase inhibitor, can elevate the risk of arrhythmias is not fully elucidated. In this study, we explored how inhibition of off‐target kinases can contribute to this phenomenon.Methods: We performed a Mendelian randomization analysis to examine the causal associations between genetically proxied inhibition of six putative ibrutinib drug targets (ErbB2/HER2, CSK, JAK3, TEC, BLK, and PLCG2) and the atrial fibrillation (AF) risk, proarrhythmic ECG indices, and cardiometabolic traits and diseases. Inverse‐variance weighted random‐effects models and Wald ratio were used to examine the associations between genetically proxied inhibition of these drug targets and the risk of outcomes. Colocalization analyses were employed to examine the robustness of the causally significant findings. ELISAs were used to measure ErbB2 levels in intracardiac plasma samples.Results: Genetically proxied ErbB2 inhibition was associated with an increased AF risk, higher P wave terminal force, and prolonged QTc interval. Patients with AF had significantly higher intracardiac ErbB2 levels compared with patients with paroxysmal supraventricular tachycardia. CSK inhibition prolonged the QRS duration, decreased the QTc interval, and was potentially linked to conduction blocks. PLCG2 inhibition led to decreased P wave terminal force, shorter QTc interval, and increased risk of left bundle branch block. BLK inhibition shortened the QTc interval and was also associated with atrioventricular block.Conclusion: The off‐target effects and downstream targets of ibrutinib, including CSK, PLCG2, ERBB2, TEC, and BLK, may lead to cardiac electrical homeostasis imbalances and lethal cardiovascular diseases. Using drugs that inhibit these targets should be given extra caution.
- 12 March 2025
- Published by Wiley in Cancer Innovation
- Vol. 4 (2) , e70004
Open AccessInhibition of Putative Ibrutinib Targets Promotes Atrial Fibrillation, Conduction Blocks, and Proarrhythmic Electrocardiogram Indices: A Mendelian Randomization Analysis
Background: The mechanism by which ibrutinib, a Bruton's tyrosine kinase inhibitor, can elevate the risk of arrhythmias is not fully elucidated. In this study, we explored how inhibition of off‐target kinases can contribute to this phenomenon.Methods: We performed a Mendelian randomization analysis to examine the causal associations between genetically proxied inhibition of six putative ibrutinib drug targets (ErbB2/HER2, CSK, JAK3, TEC, BLK, and PLCG2) and the atrial fibrillation (AF) risk, proarrhythmic ECG indices, and cardiometabolic traits and diseases. Inverse‐variance weighted random‐effects models and Wald ratio were used to examine the associations between genetically proxied inhibition of these drug targets and the risk of outcomes. Colocalization analyses were employed to examine the robustness of the causally significant findings. ELISAs were used to measure ErbB2 levels in intracardiac plasma samples.Results: Genetically proxied ErbB2 inhibition was associated with an increased AF risk, higher P wave terminal force, and prolonged QTc interval. Patients with AF had significantly higher intracardiac ErbB2 levels compared with patients with paroxysmal supraventricular tachycardia. CSK inhibition prolonged the QRS duration, decreased the QTc interval, and was potentially linked to conduction blocks. PLCG2 inhibition led to decreased P wave terminal force, shorter QTc interval, and increased risk of left bundle branch block. BLK inhibition shortened the QTc interval and was also associated with atrioventricular block.Conclusion: The off‐target effects and downstream targets of ibrutinib, including CSK, PLCG2, ERBB2, TEC, and BLK, may lead to cardiac electrical homeostasis imbalances and lethal cardiovascular diseases. Using drugs that inhibit these targets should be given extra caution.
- Open Access
- 28 February 2025
- Published by Springer Nature in Human Genomics
- Vol. 19 (1) , 1-9
Genetic insights into cardiac conduction disorders from genome-wide association studies
Substantial data support a heritable basis for cardiac conduction disorders (CCDs), but the genetic determinants and molecular mechanisms of these arrhythmias are poorly understood, therefore, we sought to identify genetic loci associated with CCDs. We performed meta-analyses of genome-wide association studies to identify genetic loci for atrioventricular block (AVB), left bundle branch block (LBBB), and right bundle branch block (RBBB) from public data from the UK Biobank and FinnGen consortium. We assessed evidence supporting the potential causal effects of candidate genes by analyzing relations between associated variants and cardiac gene expression, performing transcriptome-wide analyses, and ECG-wide phenome-wide associations for each indexed SNP. Analysis comprised over 700,000 individuals for each trait. We identified 10, 4 and 0 significant loci for AVB (PLEKHA3, TTN, FNDC3B, SENP2, SCN10A, RRH, PPARGC1A, PKD2L2, NKX2-5 and TBX20), LBBB (PPARGC1A, HAND1, TBX5, and ADAMTS5) and RBBB, respectively. Transcriptome-wide association analysis supported an association between reduced predicted cardiac expression of SCN10A and AVB. Phenome-wide associations identified traits with both cardiovascular and non- cardiovascular traits with indexed SNPs. Our analysis highlight gene regions associated with channel function, cardiac development, sarcomere function and energy modulation as important potential effectors of CCDs susceptibility.
- 28 February 2025
- Published by Springer Nature in Human Genomics
- Vol. 19 (1) , 1-9
Open AccessGenetic insights into cardiac conduction disorders from genome-wide association studies
Substantial data support a heritable basis for cardiac conduction disorders (CCDs), but the genetic determinants and molecular mechanisms of these arrhythmias are poorly understood, therefore, we sought to identify genetic loci associated with CCDs. We performed meta-analyses of genome-wide association studies to identify genetic loci for atrioventricular block (AVB), left bundle branch block (LBBB), and right bundle branch block (RBBB) from public data from the UK Biobank and FinnGen consortium. We assessed evidence supporting the potential causal effects of candidate genes by analyzing relations between associated variants and cardiac gene expression, performing transcriptome-wide analyses, and ECG-wide phenome-wide associations for each indexed SNP. Analysis comprised over 700,000 individuals for each trait. We identified 10, 4 and 0 significant loci for AVB (PLEKHA3, TTN, FNDC3B, SENP2, SCN10A, RRH, PPARGC1A, PKD2L2, NKX2-5 and TBX20), LBBB (PPARGC1A, HAND1, TBX5, and ADAMTS5) and RBBB, respectively. Transcriptome-wide association analysis supported an association between reduced predicted cardiac expression of SCN10A and AVB. Phenome-wide associations identified traits with both cardiovascular and non- cardiovascular traits with indexed SNPs. Our analysis highlight gene regions associated with channel function, cardiac development, sarcomere function and energy modulation as important potential effectors of CCDs susceptibility.
- 27 November 2024
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 32 (1) , 87-98
The Association between Serum Lipid Profile Levels and Hypertension Grades: A Cross-Sectional Study at a Health Examination Center
Introduction Hypertension and dyslipidemia are major cardiovascular risk factors that often coexist. Hyperlipidemia is a crucial modifiable risk factor in preventing cardiovascular disease. Aim We aimed to explore the relationship between lipid levels and the grading of hypertension in a community-based adult population. Methods A total of 63,091 non-employed individuals were included in this study. Measurements included systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), fasting plasma glucose (FPG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (STB), serum creatinine (SCr), blood urea nitrogen (BUN), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c). Chi-square and t-tests were used to obtain basic population characteristics. Multivariate logistic regression was used to evaluate the association between the prevalence of hypertension and lipid profiles, as well as to identify influencing factors. A P-value < 0.05 was considered statistically significant. Statistical charts were utilized to analyze the relationship between lipid parameters and hypertension grades. Results A total of 30,588 men and 32,503 women with an average age of 64.57 ± 12.5 years participated in this study. After adjusting STB and TC, every 1 mmol/L increase in TG and LDL-c was associated with a 6.0% and 6.5% increase in the prevalence of hypertension, respectively. Conversely, for every 1 mmol/L increase in HDL-c, the prevalence of hypertension decreased by 4.1%. Increases in TG and LDL-c levels were observed across all grades of hypertension, while very high HDL-c was significantly associated in grade III hypertension (1.54→1.66 mmol/L). Additionally, age, BMI, FPG, ALT, AST, SCr, and BUN significantly influenced the association between hypertension and lipid levels. Conclusion Hyperlipidemia and hypertension often coexist in health examination populations. Elevated levels of TG and LDL-C are associated with all grades of hypertension, while extremely high HDL-C level is linked to more severe hypertension. Graphical Abstract
- 27 November 2024
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 32 (1) , 87-98
The Association between Serum Lipid Profile Levels and Hypertension Grades: A Cross-Sectional Study at a Health Examination Center
Introduction Hypertension and dyslipidemia are major cardiovascular risk factors that often coexist. Hyperlipidemia is a crucial modifiable risk factor in preventing cardiovascular disease. Aim We aimed to explore the relationship between lipid levels and the grading of hypertension in a community-based adult population. Methods A total of 63,091 non-employed individuals were included in this study. Measurements included systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), fasting plasma glucose (FPG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (STB), serum creatinine (SCr), blood urea nitrogen (BUN), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c). Chi-square and t-tests were used to obtain basic population characteristics. Multivariate logistic regression was used to evaluate the association between the prevalence of hypertension and lipid profiles, as well as to identify influencing factors. A P-value < 0.05 was considered statistically significant. Statistical charts were utilized to analyze the relationship between lipid parameters and hypertension grades. Results A total of 30,588 men and 32,503 women with an average age of 64.57 ± 12.5 years participated in this study. After adjusting STB and TC, every 1 mmol/L increase in TG and LDL-c was associated with a 6.0% and 6.5% increase in the prevalence of hypertension, respectively. Conversely, for every 1 mmol/L increase in HDL-c, the prevalence of hypertension decreased by 4.1%. Increases in TG and LDL-c levels were observed across all grades of hypertension, while very high HDL-c was significantly associated in grade III hypertension (1.54→1.66 mmol/L). Additionally, age, BMI, FPG, ALT, AST, SCr, and BUN significantly influenced the association between hypertension and lipid levels. Conclusion Hyperlipidemia and hypertension often coexist in health examination populations. Elevated levels of TG and LDL-C are associated with all grades of hypertension, while extremely high HDL-C level is linked to more severe hypertension. Graphical Abstract
- Open Access
Genetic Insights into Cardiac Conduction Disorders from Genome-Wide Association Studies
BACKGROUND: Substantial data support a heritable basis for cardiac conduction disorders (CCDs), but the genetic determinants and molecular mechanisms of these arrhythmias are poorly understood, therefore, we sought to identify genetic loci associated with CCDs. METHODS: We performed meta-analyses of genome-wide association studies to identify genetic loci for atrioventricular block (AVB), left bundle branch block (LBBB), and right bundle branch block (RBBB) from public data from the UK Biobank and FinnGen consortium. We assessed evidence supporting the potential causal effects of candidate genes by analyzing relations between associated variants and cardiac gene expression, performing transcriptome-wide analyses, and ECG-wide phenome-wide associations for each indexed SNP. RESULTS: Analysis comprised over 700,000 individuals for each trait. We identified 10, 4 and 0 significant loci for AVB ( PLEKHA3, TTN, FNDC3B, SENP2, SCN10A, RRH, PPARGC1A, PKD2L2, NKX2-5 and TBX20 ), LBBB ( PPARGC1A, HAND1, TBX5 , and ADAMTS5 ) and RBBB, respectively. Transcriptome-wide association analysis supported an association between reduced predicted cardiac expression of SCN10A and AVB. Phenome-wide associations identified traits with both cardiovascular and non-cardiovascular traits with indexed SNPs. CONCLUSIONS: Our analysis highlight gene regions associated with channel function, cardiac development, sarcomere function and energy modulation as important potential effectors of CCDs susceptibility.
Open AccessGenetic Insights into Cardiac Conduction Disorders from Genome-Wide Association Studies
BACKGROUND: Substantial data support a heritable basis for cardiac conduction disorders (CCDs), but the genetic determinants and molecular mechanisms of these arrhythmias are poorly understood, therefore, we sought to identify genetic loci associated with CCDs. METHODS: We performed meta-analyses of genome-wide association studies to identify genetic loci for atrioventricular block (AVB), left bundle branch block (LBBB), and right bundle branch block (RBBB) from public data from the UK Biobank and FinnGen consortium. We assessed evidence supporting the potential causal effects of candidate genes by analyzing relations between associated variants and cardiac gene expression, performing transcriptome-wide analyses, and ECG-wide phenome-wide associations for each indexed SNP. RESULTS: Analysis comprised over 700,000 individuals for each trait. We identified 10, 4 and 0 significant loci for AVB ( PLEKHA3, TTN, FNDC3B, SENP2, SCN10A, RRH, PPARGC1A, PKD2L2, NKX2-5 and TBX20 ), LBBB ( PPARGC1A, HAND1, TBX5 , and ADAMTS5 ) and RBBB, respectively. Transcriptome-wide association analysis supported an association between reduced predicted cardiac expression of SCN10A and AVB. Phenome-wide associations identified traits with both cardiovascular and non-cardiovascular traits with indexed SNPs. CONCLUSIONS: Our analysis highlight gene regions associated with channel function, cardiac development, sarcomere function and energy modulation as important potential effectors of CCDs susceptibility.
- Open Access
N-Palmitoyl glycine activates transient receptor potential channel 5 and increases the risk of Brugada syndrome
Background: Brugada syndrome (BrS) is an arrhythmic disorder associated with an increased risk of sudden cardiac death; however, current treatment options are limited due to their side effects and variable efficacy. Methods: In this study, we first employed Mendelian randomization analysis utilizing proteomic, transcriptomic, and metabolomic data to identify potential therapeutic targets for BrS. Ex vivo perfused heart models were used to assess the effects of the potential targets on action potentials and QT intervals. Calcium indicators were employed to evaluate calcium homeostasis in primary cardiomyocytes, and patch-clamp techniques were used to investigate the impact on Nav1.5 and TRPC5 channels. Results: Our findings indicate that N-palmitoyl glycine (PalGly) is linked to an increased risk of BrS and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA. Electrophysiological experiments showed that although PalGly does not interact with Nav1.5, it enhances calcium sparks in ventricular cardiomyocytes. We determined that the calcium-modulating effect of PalGly is mediated by its binding to and activation of the transient receptor potential channel 5 (TRPC5) channel. Furthermore, PalGly was found to shorten the QT interval and action potential duration in Langendorff-perfused rabbit hearts and isolated rabbit cardiomyocytes. Transcriptomic and lipidomic analyses of PalGly-treated neonatal rat cardiomyocytes revealed significant negative modulation of immune pathways, akin to the effects observed with agonizing TRPC5. Conclusion: Our study underscores the involvement of PalGly, TRPC5, and inflammation-related proteins in the pathophysiology of BrS.
Open AccessN-Palmitoyl glycine activates transient receptor potential channel 5 and increases the risk of Brugada syndrome
Background: Brugada syndrome (BrS) is an arrhythmic disorder associated with an increased risk of sudden cardiac death; however, current treatment options are limited due to their side effects and variable efficacy. Methods: In this study, we first employed Mendelian randomization analysis utilizing proteomic, transcriptomic, and metabolomic data to identify potential therapeutic targets for BrS. Ex vivo perfused heart models were used to assess the effects of the potential targets on action potentials and QT intervals. Calcium indicators were employed to evaluate calcium homeostasis in primary cardiomyocytes, and patch-clamp techniques were used to investigate the impact on Nav1.5 and TRPC5 channels. Results: Our findings indicate that N-palmitoyl glycine (PalGly) is linked to an increased risk of BrS and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA. Electrophysiological experiments showed that although PalGly does not interact with Nav1.5, it enhances calcium sparks in ventricular cardiomyocytes. We determined that the calcium-modulating effect of PalGly is mediated by its binding to and activation of the transient receptor potential channel 5 (TRPC5) channel. Furthermore, PalGly was found to shorten the QT interval and action potential duration in Langendorff-perfused rabbit hearts and isolated rabbit cardiomyocytes. Transcriptomic and lipidomic analyses of PalGly-treated neonatal rat cardiomyocytes revealed significant negative modulation of immune pathways, akin to the effects observed with agonizing TRPC5. Conclusion: Our study underscores the involvement of PalGly, TRPC5, and inflammation-related proteins in the pathophysiology of BrS.